PRINCETON, N.J.--(BUSINESS WIRE)--PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading provider of global drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, today reported GAAP net earnings from continuing operations for its first quarter 2007 of $6.0 million, or $0.32 per diluted share, compared to $3.3 million, or $0.18 per diluted share, in the first quarter 2006.
